155 related articles for article (PubMed ID: 25002176)
21. The changing horizon of acute coronary syndrome.
de Silva R; Fox KM
Lancet; 2009 Oct; 374(9696):1125-7. PubMed ID: 19717183
[No Abstract] [Full Text] [Related]
22. Accounting for ACUITY.
Bittl JA
N Engl J Med; 2006 Nov; 355(21):2249-50. PubMed ID: 17124024
[No Abstract] [Full Text] [Related]
23. Antithrombotic therapy to support primary PCI.
Morrow DA
N Engl J Med; 2008 May; 358(21):2280-2. PubMed ID: 18499573
[No Abstract] [Full Text] [Related]
24. Bivalirudin alone in the treatment of acute myocardial infarction.
Ibrahim B
J Invasive Cardiol; 2003 Dec; 15(12):2 p following 718. PubMed ID: 14712799
[No Abstract] [Full Text] [Related]
25. Platelet reactivity and percutaneous coronary intervention: another clue in the quest for the Holy Grail of tailored antithrombotic therapy?
Di Sciascio G; Mangiacapra F
J Am Coll Cardiol; 2012 Jul; 60(5):378-80. PubMed ID: 22682552
[No Abstract] [Full Text] [Related]
26. Use of low-dose heparin with bivalirudin for ad-hoc transradial coronary interventions: experience from a single center.
Singh A; Edasery D; Noor A; Bhasin N; Kaplan B; Jauhar R
J Invasive Cardiol; 2011 Mar; 23(3):101-4. PubMed ID: 21364238
[TBL] [Abstract][Full Text] [Related]
27. The effect of differing pharmacologic strategies on infarct size in primary PCI--more confirmatory data for bivalirudin.
Kimmelstiel C
Catheter Cardiovasc Interv; 2012 Jun; 79(7):1090-1. PubMed ID: 22674760
[No Abstract] [Full Text] [Related]
28. Anticoagulant for primary percutaneous coronary intervention - the last dance for unfractionated heparin?
Silvain J; Montalescot G
Arch Cardiovasc Dis; 2012 May; 105(5):259-61. PubMed ID: 22709466
[No Abstract] [Full Text] [Related]
29. Unfractionated heparin versus bivalirudin in patients undergoing primary percutaneous coronary intervention: a SWEDEHEART study.
Grimfjärd P; Erlinge D; Koul S; Lagerqvist B; Svennblad B; Varenhorst C; James SK
EuroIntervention; 2017 Mar; 12(16):2009-2017. PubMed ID: 28044990
[TBL] [Abstract][Full Text] [Related]
30. Cost analysis of bivalirudin in percutaneous coronary intervention.
Lauer MA
J Invasive Cardiol; 2000 Dec; 12 Suppl F():37F-40. PubMed ID: 11156733
[No Abstract] [Full Text] [Related]
31. Profile of bleeding and ischaemic complications with bivalirudin and unfractionated heparin after percutaneous coronary intervention.
Iijima R; Ndrepepa G; Mehilli J; Byrne RA; Schulz S; Neumann FJ; Richardt G; Berger PB; Schömig A; Kastrati A
Eur Heart J; 2009 Feb; 30(3):290-6. PubMed ID: 19147609
[TBL] [Abstract][Full Text] [Related]
32. Regulation of PAR-1 in patients undergoing percutaneous coronary intervention: effects of unfractionated heparin and bivalirudin.
Eslam RB; Reiter N; Kaider A; Eichinger S; Lang IM; Panzer S
Eur Heart J; 2009 Aug; 30(15):1831-6. PubMed ID: 19468011
[TBL] [Abstract][Full Text] [Related]
33. Otamixaban in acute coronary syndromes.
Eikelboom JW; Weitz JI
Lancet; 2009 Sep; 374(9692):762-4. PubMed ID: 19717186
[No Abstract] [Full Text] [Related]
34. Economic impact of new interventional therapies: are we asking the right questions?
Kong DF; Mark DB
J Am Coll Cardiol; 2004 Nov; 44(9):1809-11. PubMed ID: 15519011
[No Abstract] [Full Text] [Related]
35. Anticoagulation during percutaneous coronary intervention in diabetics--is simpler always better?
Meier P; Gurm HS
J Invasive Cardiol; 2010 Mar; 22(3):101-2. PubMed ID: 20197574
[No Abstract] [Full Text] [Related]
36. Intracoronary macrothrombus formation during percutaneous coronary intervention despite optimal activated clotting time using bivalirudin--a case report.
Tadros GM; Broder K; Bachour F
Angiology; 2005; 56(6):761-5. PubMed ID: 16327953
[TBL] [Abstract][Full Text] [Related]
37. [The HEAT-PPCI study].
Saia F; Dall'Ara G; Calabrò P
G Ital Cardiol (Rome); 2015 Feb; 16(2):65-70. PubMed ID: 25805088
[No Abstract] [Full Text] [Related]
38. Outcomes of Patients with coronary artery perforation complicating percutaneous coronary intervention and correlations with the type of adjunctive antithrombotic therapy: pooled analysis from REPLACE-2, ACUITY, and HORIZONS-AMI trials. Heparin only should be considered for lesions at high risk for perforation.
Movahed MR
J Interv Cardiol; 2010 Apr; 23(2):203. PubMed ID: 20236210
[No Abstract] [Full Text] [Related]
39. Direct thrombin inhibitors (part 2 of 2).
Arora UK; Dhir M
J Invasive Cardiol; 2005 Feb; 17(2):85-91. PubMed ID: 15687531
[No Abstract] [Full Text] [Related]
40. Clinical applications of bivalirudin in the cardiac catheterization laboratory.
Thompson KA; Philip KJ; Schwarz ER
J Cardiovasc Pharmacol Ther; 2011 Jun; 16(2):140-9. PubMed ID: 21097669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
